|
INDUSTRY DEEP DIVE
Your portfolio says "pharma." It's actually two industries moving in opposite directions.
We ran pharma through our 8-dimension engine and something unusual happened.
The scores for Big Pharma and AI-native biotech diverged so dramatically that we permanently split them into separate industries in the model. Here's the short version:
| Dimension |
Big Pharma |
Biotech-AI |
| Current Adoption |
0.18 |
0.51 |
| AI Ceiling |
0.93 |
1.00 |
| Competitive Moat |
+0.85 |
+0.65 |
| Resistance |
0.87 |
0.70 |
Big Pharma is barely started (0.18 adoption) but has an impenetrable data moat built on 30 years of clinical trial data. Biotech-AI is halfway there (0.51) with near-maximum velocity — but historically, companies like these get acquired before reaching scale.
The full report covers:
- All 8 engine dimensions for both industries, with explanations
- 12 cross-industry cascade effects (pharma disruption ripples into healthcare, insurance, cloud, semis, and more)
- The $2.5B-to-$250M drug discovery cost collapse timeline
- The "Innovator vs. Payer" tension that determines whether pharma keeps its margins or governments demand 90% price cuts
- Why the strongest effect in our pharma model is chip design feeding into biotech at 0.95 strength
How we built this analysis: Our engine scores 28 industries across 8 analytical dimensions using 324 expert-sourced data points, models 167 cross-industry cascade effects, and runs boom/base/doom scenarios across 5 timeframes (1, 2, 3, 5, and 10 years). The pharma split was discovered when the engine's own scoring diverged too widely for a single industry classification. See the full matrix here.
This is the first in our biweekly industry deep dive series. Every 2 weeks: one industry, fully scored, with cross-effects mapped. Next up: a different industry from our 28-sector model.
|